Evidence map›Paper›PMID 31582836›Full record

ArticleOncogene2020

SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.

Branden A Smeester, Nicholas J Slipek, Emily J Pomeroy, Heather E Bomberger, Ghaidan A Shamsan, Joseph J Peterson, Margaret R Crosby, Garrett M Draper, Kelsie L Becklin, Eric P Rahrmann and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma.Journal of experimental & clinical cancer research : CR · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Implication ofMolecular cancer therapeutics · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Branden A SmeesterDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Nicholas J SlipekDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Emily J PomeroyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-7690-3570
Heather E BombergerDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.
Ghaidan A ShamsanMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Joseph J PetersonDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Margaret R CrosbyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Garrett M DraperDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Kelsie L BecklinDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Eric P RahrmannCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
James B McCarthyMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
David J OddeMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
David K WoodDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.
David A LargaespadaDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Branden S MoriarityDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA. mori0164@umn.edu.
University of Minnesota · USUniversity of Cambridge · GB

Funding

Musculoskeletal Training GrantT32AR050938 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CLOHISY, DENIS R · 2004 to 2020
$3.0M
Stem Cell Biology Training ProgramT32GM113846 · NIGMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2015 to 2019
$712k
NIAMS NIH HHS T32 AR050938NIGMS NIH HHS T32 GM113846
6 · The paper itself

Abstract

Semaphorins, specifically type IV, are important regulators of axonal guidance and have been increasingly implicated in poor prognoses in a number of different solid cancers. In conjunction with their cognate PLXNB family receptors, type IV members have been increasingly shown to mediate oncogenic functions necessary for tumor development and malignant spread. In this study, we investigated the role of semaphorin 4C (SEMA4C) in osteosarcoma growth, progression, and metastasis. We investigated the expression and localization of SEMA4C in primary osteosarcoma patient tissues and its tumorigenic functions in these malignancies. We demonstrate that overexpression of SEMA4C promotes properties of cellular transformation, while RNAi knockdown of SEMA4C promotes adhesion and reduces cellular proliferation, colony formation, migration, wound healing, tumor growth, and lung metastasis. These phenotypic changes were accompanied by reductions in activated AKT signaling, G1 cell cycle delay, and decreases in expression of mesenchymal marker genes SNAI1, SNAI2, and TWIST1. Lastly, monoclonal antibody blockade of SEMA4C in vitro mirrored that of the genetic studies. Together, our results indicate a multi-dimensional oncogenic role for SEMA4C in metastatic osteosarcoma and more importantly that SEMA4C has actionable clinical potential.

Indexed as

Disease ProgressionBone NeoplasmsCarcinogenesisCell Line, TumorCell ProliferationCell Transformation, NeoplasticGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansLung NeoplasmsNeoplasm MetastasisOsteosarcomaSemaphorinsSema4c protein, humanSemaphorins

Identifiers

PMID31582836
OpenAlexW2978206908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.